

Exploring *Helicobacter pylori* infection, diagnosis, and prospect

Md. Aktaruzzaman  

Department of Pharmacy, Jahangirnagar University, Dhaka-1342, Bangladesh

Received: 19-05-2025, Accepted: 21-06-2025, Published online: 22-06-2025



Copyright© 2025. This open-access article is distributed under the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HOW TO CITE THIS

Aktaruzzaman Md. (2025) Exploring *helicobacter pylori* infection, diagnosis, and prospect.
Mediterr J Med Med Sci. [Article number: 3]. 1(1): 14-21. <https://doi.org/10.5281/zenodo.15713051>

Keywords: Antibiotic, gut, infection, peptic ulcer

Abstract: *Helicobacter pylori* is a gram-negative, short helical, S-shaped microbe that is 0.5-1 micrometer broad and 2-4 micrometer long. It causes chronic gastric infections and is primarily located in the pyloric area of the stomach. It is believed that almost half of the world's population is infected with these bacteria. Although the precise mechanism of *Helicobacter pylori* infection and transmission remains unknown, it is believed that the fecal-oral and oral-oral pathways, facilitated by food or water consumption, are prevalent. The pathogenicity, microbial activity, genetic predisposition, and clinical therapies of *Helicobacter pylori*-induced gastric atrophy and gastric cancer have garnered more attention in the past three decades. Research has indicated that *Helicobacter pylori* infection may influence the prevalence of malnutrition in specific risk groups and that it may be linked to the inability to absorb vital minerals. An adequate and balanced diet, particularly one that is high in fruits and vegetables and low in processed salty foods, has been shown to have a protective effect against the consequences of *Helicobacter pylori* infection. On the other hand, dietary factors may play a significant role in H. pylori infection. The current review offers a comprehensive summary of every facet of *Helicobacter pylori* infection, including advanced treatment and diagnosis.

Introduction

About 50.0% of people worldwide suffer from a persistent infection caused by *Helicobacter pylori* (H. pylori) [1]. 1.0-3.0% of people with H. pylori infection develop gastric cancer (GC), which makes up 90.0% of all non-cardia GC (NCGC) and 20.0% of all cardia (CGC) cases. H. pylori are also responsible for 15.0% of the world's cancer burden [2, 3]. A threefold increase in CGC risk and a sixfold rise in NCGC risk may result from infection [4]. Furthermore, H. pylori infection is frequently the origin of all precancerous forms of GC, including gastric hyperplastic polyps generated from the stomach epithelium, metaplasia, foveolar hyperplasia, and chronic atrophic gastritis (CAG) [5]. Immunologically, it can avoid host immune clearance and continue to occupy the niches, which eventually causes pattern recognition receptors on neutrophils, stomach epithelial cells, and antigen-presenting cells to become active [7]. Furthermore, H. pylori cause leukocytes and gastric epithelial cells to activate NF- κ B [7], which contributes to the long-term colonization of H. pylori, the chronic inflammatory microenvironment, clinical symptoms (**Figure 1**), and aberrant apoptosis. These factors further cause the accumulation of mutations and malignant transformation of gastric epithelial cells [8]. Another major component contributing to GC is oncoprotein cytotoxin-associated gene A (CagA), which inactivates tumor suppressors and stimulates oncogenic signaling pathways [9]. Before GC endoscopic or barium photofluorographic screening, H. pylori identification and eradication techniques are useful for GC prevention, particularly in regions with elevated GC risks [10, 11]. Idiopathic thrombocytopenic

purpura, vitamin B12 insufficiency, and unexplained iron-deficiency anemia are among the extra-gastric illnesses that have been strongly linked to *H. pylori*. Identifying and eliminating *H. pylori* in patients suffering from these illnesses is also advised [12]. Hepatobiliary disorders [15, 16], cardiovascular disorders [14], neurological disorders [13], and autoimmune disorders may also be impacted by *H. pylori* infection. This review's objective is to present current information on *H. pylori* infection diagnosis and therapy.




Figure 1: Symptoms of infection *Helicobacter pylori* [13]

H. pylori infection epidemiology: Despite claims that half of the world's population has an *H. pylori* infection, additional evidence-based study is required. This infection is more common in developing nations and among those with lower socioeconomic positions [17]. According to Vilaichone et al. [18], there are regional variations in *H. pylori* prevalence within a single nation as well as variations between nations. Determining its prevalence is extremely challenging because no health system in developing nations accumulates registry-based data on *H. pylori* prevalence [19]. Globally, there are an estimated 4.4 billion *H. pylori*-infected individuals, based on regional prevalence estimates [20]. Switzerland had the lowest *H. pylori* burden, while Nigeria, Portugal, Estonia, Kazakhstan, and Pakistan had the highest burden relative to the overall population [21]. According to Mezmale et al. [22], Russia, Jordan, Iran, China, Canada, and Latin American nations had high rates of *H. pylori* infection.

According to a 2011 study by Özen et al. [23], 161 out of 473 students in four separate Istanbul primary and secondary schools tested positive for *H. pylori*. The C-urea breath test was also used in 2013 to screen 4622 individuals in 55 cities for *H. pylori* infection, and 3852 individuals (2075 females and 1777 men) tested positive [24]. In a 2019 study by Soyulu et al. [25], biopsy samples from 88 patients (53 females and 35 males) with dyspeptic complaints revealed that 46 patients (21 females and 25 males) had *H. pylori*-positive status. Male patients were found to be more *H. pylori*-positive than the overall number of participants. 18.2% of toddlers aged 06 to 59 months, 14.0% of boys and 16.0% of girls aged 10 to 19 years, and 40.0% of non-pregnant women aged 20 to 49 years had *H. pylori* infection, according to a study done in Nepal [26].

Transmission of H. pylori: It is believed that *H. pylori* can spread either directly from one person to another or indirectly from the environment to humans, while the precise route of transmission is unknown [27]. Particularly in industrialized nations, person-to-person transmission is believed to be the main mechanism of transmission. In impoverished nations, food and waterborne transmission are more common, and *H. pylori* spreads more quickly in unsanitary environments [28-30]. People who consume raw vegetables are more likely to be infected, according to a study by Goodman et al. assessing the incidence of *H. pylori* infection in the rural community. Additionally, consuming water from streams and rivers and swimming in them might raise the risk of infection due to pollution from unpurified or irrigation water [31]. It is believed that sexual, gastric-oral, fecal-oral, or oral-oral pathways are the means of person-to-person transmission [27]. According to the literature, *H. pylori* can be found in the saliva and dental plaque of infected people [32, 33], demonstrating that the illness spreads far more quickly than anticipated and that transmission between family members is particularly common [34].

Diagnosis process: There are numerous ways to identify an *H. pylori* infection [35]. The organism is mostly found in the stomach due to its trophic status for gastric epithelium, where it produces the distinctive and easily identifiable histologic pattern of acute-on-chronic inflammation [36]. Generally speaking, organisms are common and can be found with particular stains, the most precise of which is immunohistochemistry employing antibodies specific to *H. pylori* [37]. Numerous tests are available, ranging from molecular testing using next-generation sequencing to serologic testing for anti-*H. pylori* IgG antibodies [38]. While endoscopy is necessary for some tests to sample the stomach contents, others are noninvasive. Noninvasive testing is often recommended [39]. In addition to the clinical indication, the diagnostic approach should take patient preferences, local test costs, and availability into account. There are several commercially available tests for anti-*H. pylori* IgG, and the presence of the infection triggers a serum immune response. Serology was the most widely utilized diagnostic test until recently [40]. Currently, serology is typically not covered by Medicare and is not advised. Although some labs offer IgA and IgM anti-*H. pylori* testing, these tests are typically not authorized by the US Food and Drug Administration (FDA) and are not advised or reliable due to their poor sensitivity and specificity. Because commercial laboratories also provide and frequently favor utilizing in-house developed tests with unclear specificity and sensitivity, it is crucial to request only FDA-approved tests when working with large commercial laboratories in the United States. IgG, IgA, and IgM test panels typically comprise unapproved, unclearly diagnostic tests and offer little additional value above IgG testing. Serologic testing results should not be the sole basis for making treatment decisions because they can remain positive for a long time after the virus has been cleared (a serologic "scar"). Currently, a very high pretest probability of an *H. pylori*-related condition, such as an active duodenal ulcer, is one of the requirements for using IgG serology. Before beginning treatment, it is advised that the existence of an active infection be verified by a urea breath test (UBT), stool antigen test, or endoscopy, depending on the presentation, if serology is performed without a very high pretest chance. The clinical scenario determines which diagnostic method is used. For instance, endoscopy combined with *H. pylori* testing would be the most effective test for a patient exhibiting symptoms and indicators of a serious upper gastrointestinal condition, such as stomach cancer or a peptic ulcer. On the other hand, a noninvasive test like the stool antigen test or UBT would probably be more beneficial for an asymptomatic relative of a patient with peptic ulcer disease, provided that only stool antigen tests employing monoclonal antibodies are employed [41].

H. pylori and peptic ulcer: Peptic ulcer disease typically develops asymptotically and is a major cause of morbidity and mortality globally. Epigastric pain accompanied by bloating, dyspepsia, nausea, early satiety, or abdominal fullness are signs of symptomatic peptic ulcer disease [42, 43]. The stomach and proximal duodenum are common sites for peptic ulcer detection [44]. The majority of peptic ulcer disease cases are believed to be related to either nonsteroidal anti-inflammatory drug (NSAID) use, *H. pylori* infection, or both [45]. Because there is less somatostatin in the antrum, those with non-atrophic antral-dominant gastritis have higher amounts of gastrin and highly accelerated acid production. Clinically, this group frequently has

duodenal ulcers [39]. Research has indicated that the removal of *H. pylori* can improve peptic ulcers [46, 47]. The gastric/duodenal mucosa is chronically colonized by *H. pylori*, which causes innate and specific immune responses as well as gastroduodenal disorders such as gastritis and peptic ulcers. Still, if the infection is not eradicated, the chronic active gastritis state may last a lifetime [48].

Current standard treatment protocols for Helicobacter pylori: The first-line treatment for patients in regions with high *H. pylori* clarithromycin resistance is bismuth quadruple therapy or nonbismuth concurrent quadruple therapy for 10-14 days, according to Clinical Guideline [49] (North America). Two different kinds of antibiotics, bismuth, and a proton pump inhibitor (PPI) make up bismuth quadruple treatment. Traditionally, the antibiotics that were included were tetracycline and metronidazole; more recently, amoxicillin, clarithromycin, and tinidazole have been included. A PPI and three different kinds of antibiotics, usually amoxicillin, clarithromycin, and metronidazole, make up concurrent quadruple treatment. In actual clinical practice in Europe, extensive observational studies have proven adequate eradication results (>90.0%) for both therapy modalities [50]. Clarithromycin-containing triple therapy is only advised by the previously mentioned guidelines in regions with low levels of clarithromycin resistance and in patients who have not previously taken macrolide antibiotics [51]. As an empirical treatment, 10- to 14-day bismuth quadruple therapy is also advised in Asia by the Chinese guidelines [52]. However, conventional triple therapy, which includes clarithromycin, is still advised as the first line of treatment in the Korean [53] and Japanese [54] guidelines. According to Korean guidelines, nonbismuth quadruple therapy (concurrent and sequential therapies) should be utilized as an empirical first-line treatment and triple therapy should have a longer treatment period of 14 days. Antimicrobial stewardship principles evaluate antimicrobial treatments according to their absolute cure rate, which is the capacity to consistently attain a predetermined cure rate, like $\geq 95.0\%$ with susceptible infections. Additionally, suggested treatments are tailored to consistently produce the greatest cure rates. All facets of therapy, including medication choice, dose, duration, dosing intervals, and administration in connection with meals, are included in the optimization. Empirical therapy is by definition limited to treatment plans that have been shown to consistently produce high cure rates in the target group. It is recommended that clinical programs that incorporate the evaluation of targeted cure rates be implemented in order to monitor treatment outcomes, inform physicians and public health officials of the results, and alert them when cure rates start to decline [55]. (**Table 1**) lists the *H. pylori* eradication treatments currently in use worldwide along with their eradication rates. As the regularly used regimens vary by location and country due to variations in medical insurance coverage and drug availability, it is challenging to directly compare the effectiveness of each regimen in order to identify the "best" regimen.

Table 1: Current first-line *H. pylori* treatment protocols and rates of eradication

Drug regimen	PPI	Antibiotics	Duration (days)	Eradication rate per protocol	References
High-dose PPI-amoxicillin dual therapy	Esomeprazole (20 mg qid)	AMO (750 mg qid)	14	92.0%	[56]
PPI-based standard triple therapy	Lansoprazole (30 mg bid)	AMO (1000 mg bid); CLA (500 mg bid)	14	63.0%	[57]
Reverse hybrid therapy	Dexlansoprazole (60 mg qd)	AMO (1,000 mg bid); CLA (500 mg bid)	14	96.0%	[58]
Concomitant quadruple therapy	Esomeprazole (20 mg bid)	AMO (1,000 mg bid); CLA (500 mg bid); MET (500 mg bid)	14	94.0%	[59]
Bismuth quadruple therapy	Lansoprazole (30 mg bid)	MET (500 mg tid); TET (500 mg qid); Bismuth (300 mg qid)	10	93.0%	[60]

Key: AMO, amoxicillin; bid, twice daily; CLA, clarithromycin; MET, metronidazole; PPI, proton pump inhibitor; qd, once daily; qid, 4 times daily; TET, tetracycline; tid, 3 times daily.

Future directions: As gastroenterologists increasingly accept the idea that effective therapy delivery necessitates replacing the tried-and-true techniques used to treat infectious diseases with the trial-and-error approach that has defined *H. pylori* therapy since its inception, the management of *H. pylori* infection is undergoing a significant transformation [61]. The etiology of the common gastrointestinal disease is not known; there is a high placebo response to treatment, treatment success is limited, and true cures are uncommon [62]. When combined, these features necessitate that treatment trials include a comparator, frequently a placebo, and concentrate on comparing treatment success with a placebo or another antibiotic. The capacity to consistently attain high cure rates and the absence of a placebo response, on the other hand, make true cure rates the main outcome variable when considering *H. pylori* gastritis as an infectious condition. Future *H. pylori* therapy trials will concentrate on the real cure rate, and comparisons will be limited to selecting one of two extremely effective treatments. To do this, the previous strategy and most of the existing treatment recommendations that are based on comparisons of frequently ineffective medications must be abandoned. Given that the emphasis is now on finding locally highly effective therapies and creating feedback loops to assist clinicians in identifying, optimizing, utilizing, monitoring, and, when necessary, modifying the recommended regimens to ensure continuing locally highly effective therapy, those skilled in the prior art of treating *H. pylori* gastritis as another gastroenterological disease rather than an infectious disease may find the transition challenging.

Conclusion: Recent studies have unequivocally demonstrated the pathogenicity, microbial activity, and genetic propensity to aid in understanding the severity of *H. pylori*-caused gastric atrophy and gastric cancer. It is anticipated that this circumstance will have a beneficial impact on the therapeutic process. Combination therapies, such as those including probiotics and phytochemicals from natural sources, appear to be effective in eliminating *H. pylori*. It is crucial to ensure adequate nutrition by having qualified dietitians determine the best course of action and implement a diet that is appropriate for the individual. Furthermore, probiotics added to treatment plans have shown some encouraging results; still, more thorough research is required. Above all, a diet high in fruits and vegetables and low in processed meats and salt has good preventive potential, particularly against cancer and *H. pylori* eradication. Furthermore, possible substitute therapies could supplement the present antibiotic regimen. The development of a vaccine could be one way to accomplish a variety of eradication and preventive measures.

References

1. Hooi, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology*. 2017; 153(2): 420-429. doi: 10.1053/j.gastro.2017.04.022
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA; A Cancer Journal for Clinicians*. 2018; 68(6): 394-424. doi: 10.3322/caac.21492
3. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. *The Lancet, Global Health*. 2016; 4(9): e609-616. doi: 10.1016/S2214-109X(16)30143-7
4. Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with *Helicobacter pylori* infection in China: A case-cohort study. *The Lancet, Public Health*. 2021; 6(12): e888-e896. doi: 10.1016/S2468-2667(21)00164-X
5. Yang H, Yang WJ, Hu B. Gastric epithelial histology and precancerous conditions. *World Journal of Gastrointestinal Oncology*. 2022; 14(2): 396-412. doi: 10.4251/wjgo.v14.i2.396
6. Yang H, Hu B. Immunological Perspective: *Helicobacter pylori* Infection and Gastritis. *Mediators of Inflammation*. 2022; 2022: 2944156. doi: 10.1155/2022/2944156
7. Maubach G, Vieth M, Boccellato F, Naumann M. *Helicobacter pylori*-induced NF- κ B: trailblazer for gastric pathophysiology. *Trends in Molecular Medicine*. 2022; 28(3): 210-222. doi: 10.1016/j.molmed.2021.12.005

8. Lin M, Tu RH, Wu SZ, Zhong Q, Weng K, Wu YK, et al. Increased ONECUT2 induced by *Helicobacter pylori* promotes gastric cancer cell stemness via an AKT-related pathway. *Cell Death and Disease*. 2024; 15(7): 497. doi: 10.1038/s41419-024-06885-2
9. Wang J, Deng R, Chen S, Deng S, Hu Q, Xu B, et al. *Helicobacter pylori* CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. *iScience*. 2023; 26(12): 108414. doi: 10.1016/j.isci.2023.108414
10. Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. *Helicobacter pylori* eradication for the prevention of gastric neoplasia. *The Cochrane Database of Systematic Review*. 2020; 7(7): CD005583. doi: 10.1002/14651858.CD005583.pub3
11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. 2018; 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
12. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, et al. Management of *Helicobacter pylori* infection: the Maastricht VI/Florence consensus report. *Gut*. 2022; gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745
13. Kira JI, Isobe N. *Helicobacter pylori* infection and demyelinating disease of the central nervous system. *Journal of Neuroimmunology*. 2019; 329: 14-19. doi: Nil.
14. Lee M, Baek H, Park JS, Kim S, Kyung C, Baik SJ. Current *Helicobacter pylori* infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. *PLoS One*. 2018; 13(3): e0193646. doi: 10.1371/journal.pone.0193646
15. Wang L, Chen J, Jiang W, Cen L, Pan J, Yu C, et al. The relationship between *Helicobacter pylori* infection of the gallbladder and chronic cholecystitis and cholelithiasis: A systematic review and meta-Analysis. *Canadian Journal of Gastroenterology and Hepatology*. 2021; 2021: 8886085. doi: 10.1155/2021/8886085
16. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. *Frontiers in Immunology*. 2024; 15: 1339971. doi: 10.3389/fimmu.2024.1339971
17. Lehours P. Actual diagnosis of *Helicobacter pylori* infection. *Minerva Gastroenterologica e. Dietologica*. 2018; 64: 267-279. doi: 10.23736/S1121-421X.18.02494-7
18. Vilaichone RK, Mahachai V, Shiota S, Uchida T, Ratanachu-ek T, Tshering L, et al. Extremely high prevalence of *Helicobacter pylori* infection in Bhutan. *World Journal of Gastroenterology*. 2013; 19(18): 2806-2810. doi: 10.3748/wjg.v19.i18.2806
19. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of *Helicobacter pylori* infection: Systematic review and meta-analysis. *Gastroenterology*. 2017; 153(2): 420-429. doi: 10.1186/s12879-023-08504-5
20. Mard SA, Khadem Haghighian H, Sebghatulahi V, Ahmadi B. Dietary factors in relation to *Helicobacter pylori* infection. *Gastroenterology Research and Practice*. 2014; 2014: 826910. doi: 10.1155/2014/826910
21. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Buruoa C. Prevalence of *Helicobacter pylori* and its associated factors among healthy asymptomatic residents in the United Arab Emirates. *Pathogens*. 2019; 8(2): 44. doi: 10.3390/pathogens8020044
22. Mezmaile L, Coelho LG, Bordin D, Leja M. Review: Epidemiology of *Helicobacter pylori*. *Helicobacter*. 2020; 25 Suppl 1: e12734. doi: 10.1111/hel.12734
23. Ozen A, Furman A, Berber M, Karatepe HO, Mutlu N, Sariçoban HE, Büyükgebiz B. The effect of *Helicobacter pylori* and economic status on growth parameters and leptin, ghrelin, and insulin-like growth factor (IGF)-I concentrations in children. *Helicobacter*. 2011; 16(1): 55-65. doi: 10.1111/j.1523-5378.2010.00814.x
24. Lin SK, Lambert JR, Schembri MA, Nicholson L, Korman MG. *Helicobacter pylori* prevalence in endoscopy and medical staff. *Journal of Gastroenterology and Hepatology*. 1994; 9(4): 319-324. doi: 10.1111/j.1440-1746.1994.tb01249.x
25. Soylu A, Peker KD, Yirgin H, Polat S, et al. Evaluation of *H. pylori* and Histopathological findings in patients with dyspepsia. *Journal of Medical Faculty Clinics* 2019; 2(4): 139-141. doi: Nil.
26. Mehata S, Parajuli KR, Pant ND, Rayamajhee B, Yadav UN, Mehta RK, et al. Prevalence and correlates of *Helicobacter pylori* infection among under-five children, adolescent and non-pregnant women in Nepal: Further analysis of Nepal national micronutrient status survey 2016. *PLoS Neglected Tropical Disease*. 2021; 15(6): e0009510. doi: 10.1371/journal.pntd.0009510
27. Zamani M, Vahedi A, Maghdouri Z, Shokri-Shirvani J. Role of food in environmental transmission of *Helicobacter pylori*. *Caspian Journal of Internal Medicine*. 2017; 8(3): 146-152. doi: 10.22088/cjim.8.3.146
28. Vale FF, Vitor JM. Transmission pathway of *Helicobacter pylori*: Does food play a role in rural and urban areas? *Internal Journal of Food Microbiology*. 2010; 138(1-2): 1-12. doi: 10.1016/j.ijfoodmicro.2010.01.016

29. Zhang YY, Xia HH, Zhuang ZH, Zhong J. Review article: 'true' re-infection of *Helicobacter pylori* after successful eradication-worldwide annual rates, risk factors and clinical implications. *Alimentary Pharmacology and Therapeutics*. 2009; 29(2): 145-60. doi: 10.1111/j.1365-2036.2008.03873.x
30. Goodman KJ, Correa P, Tenganá Aux HJ, Ramírez H, DeLany JP, Guerrero Pepinosa O, et al. *Helicobacter pylori* infection in the Colombian Andes: a population-based study of transmission pathways. *American Journal of Epidemiology*. 1996; 144(3): 290-299. doi: 10.1093/oxfordjournals.aje.a008924
31. Rafi IK (2025) Natural treatment for nausea and vomiting: A short message. *Mediterranean Journal of Medical Research*. 2: 32-37. doi: 10.5281/zenodo.15427363
32. Nisha KJ, Nandakumar K, Shenoy KT, Janam P. Periodontal disease and *Helicobacter pylori* infection: A community-based study using serology and rapid urease test. *Journal of Investigative and Clinical Dentistry*. 2016; 7(1): 37-45. doi: 10.1111/jicd.12122
33. Aksit Bıçak D, Akyuz S, Kıratlı B, Usta M, Urgancı N, Alev B, Yarat A, Sahin F. The investigation of *Helicobacter pylori* in the dental biofilm and saliva samples of children with dyspeptic complaints. *BMC Oral Health*. 2017; 17(1): 67. doi: 10.1186/s12903-017-0361-x
34. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of *Helicobacter pylori* infection and public health implications. *Helicobacter*. 2011; 16 Suppl 1(0 1): 1-9. doi: 10.1111/j.1523-5378.2011.00874.x
35. Dore MP, Pes GM. What is new in *Helicobacter pylori* diagnosis: An overview. *Journal of Clinical Medicine*. 2021; 10(10): 2091. doi: 10.3390/jcm10102091
36. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *American Journal of Surgery and Pathology*. 1996; 20(10): 1161-1181. doi: 10.1097/00000478-199610000-00001
37. Glickman JN, Noffsinger A, Nevin DT, Ray M, Lash RH, Genta RM. *Helicobacter* infections with rare bacteria or minimal gastritis: Expecting the unexpected. *Digestive and Liver Disease*. 2015; 47(7): 549-555. doi: 10.1016/j.dld.2015.04.005
38. Lash RH, Genta RM. Routine anti-*Helicobacter* immunohistochemical staining is significantly superior to reflex staining protocols for the detection of *Helicobacter* in gastric biopsy specimens. *Helicobacter*. 2016; 21(6): 581-585. doi: 10.1111/hel.12315
39. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut*. 2017; 66(1): 6-30. doi: 10.1136/gutjnl-2016-312288
40. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on Testing for *Helicobacter pylori* Infection in the United States. *Clin Gastroenterol Hepatol*. 2018; 16(7): 992-1002.e6. doi: 10.1016/j.cgh.2018.03.013
41. Gisbert JP, de la Morena F, Abaira V. Accuracy of monoclonal stool antigen test for the diagnosis of *H. pylori* infection: a systematic review and meta-analysis. *American Journal of Gastroenterology*. 2006; 101(8): 1921-1930. doi: 10.1111/j.1572-0241.2006.00668.x
42. Kavitt RT, Lipowska AM, Anyane-Yeboah A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. *American Journal of Medicine*. 2019; 132(4): 447-456. doi: 10.1016/j.amjmed.2018.12.009
43. Rafi IK, Aktaruzzaman Md (2025) Lifestyle and nutritional deficiencies associated with vegetarian diets. *Mediterranean Journal of Medical Research*. 02: 20-25. doi: 10.5281/zenodo.15336103
44. Ramakrishnan K, Salinas RC. Peptic ulcer disease. *American Family Physician*. 2007; 76(7): 1005-1012. PMID: 17956071.
45. Yeo SH, Yang CH. Peptic ulcer disease associated with *helicobacter pylori* infection. *Korean Journal of Gastroenterology*. 2016; 67(6): 289-299. doi: 10.4166/kjg.2016.67.6.289
46. Wong CS, Chia CF, Lee HC, Wei PL, Ma HP, Tsai SH, Wu CH, Tam KW. Eradication of *Helicobacter pylori* for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. *Journal of Surgery and Research*. 2013; 182(2): 219-226. doi: 10.1016/j.jss.2012.10.046
47. Seo SI, Kim SJ, Kim HS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY. Is there any difference in the eradication rate of *Helicobacter pylori* infection according to the endoscopic stage of peptic ulcer disease? *Helicobacter*. 2015; 20(6): 424-430. doi: 10.1111/hel.12221
48. Jinling X, Guoan L, Chuxi C, Qiaoyuan L, Yinzong C, Shihao C, et al. NOTCH1 is positively correlated with IL17F in *Helicobacter pylori* infection and a biomarker for mucosal injury. *iScience*. 2024; 27(7): 110323. doi: 10.1016/j.isci.2024.110323
49. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. *American Journal of Gastroenterology*. 2017; 112(2): 212-239. doi: 10.1038/s41395-018-0132-6
50. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al. European registry on *Helicobacter pylori* management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. *Gut*. 2021; 70(1): 40-54. doi: 10.1136/gutjnl-2020-321372

51. Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal *Helicobacter pylori* treatment for the present and the future. *Digestion*. 2022; 103(1): 62-68. doi: 10.1159/000519413
52. Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of *Helicobacter pylori* infection. *Helicobacter*. 2018; 23(2): e12475. doi: 10.1111/hel.12475
53. Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, et al. Evidence-based guidelines for the treatment of *Helicobacter pylori* infection in Korea 2020. *Gut and Liver*. 2021; 15(2): 168-195. doi: 10.5009/gnl20288
54. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of *Helicobacter pylori* infection in Japan: 2016 Revised Edition. *Helicobacter*. 2019; 24(4): e12597. doi: 10.1111/hel.12597
55. Lee YC, Dore MP, Graham DY. Diagnosis and treatment of *Helicobacter pylori* infection. *Annual Review of Medicine*. 2022; 73: 183-195. doi: 10.1146/annurev-med-042220-020814
56. Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line *Helicobacter pylori* infection eradication: A randomized trial. *Helicobacter*. 2020; 25(6): e12762. doi: 10.1111/hel.12762
57. Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and cost-effectiveness comparison of 10-day, 14-day sequential versus 14-day triple therapies for treating *Helicobacter pylori* infection in Egyptian patients. *Journal of Clinical Gastroenterology*. 2020; 54(9): 806-812. doi: 10.1097/MCG.0000000000001278
58. Hsu PI, Tsay FW, Kao JY, Peng NJ, Tsai KW, Tsai TJ, et al. Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of *Helicobacter pylori* infection. *Journal of Gastroenterology and Hepatology*. 2020; 35(10): 1731-1737. doi: 10.1111/jgh.15034
59. Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, et al. 10-day versus 14-day quadruple concomitant nonbismuth therapy for the treatment of *Helicobacter pylori* infection: Results from a randomized prospective study in a high clarithromycin resistance country. *Journal of Clinical Gastroenterology*. 2020; 54(6): 522-527. doi: 10.1097/MCG.0000000000001328
60. Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the *Helicobacter pylori* infection in Korea: a randomized open-label trial. *BMC Gastroenterology*. 2021; 21(1): 95. doi: 10.1186/s12876-021-01680-1
61. Graham DY. Transitioning of *Helicobacter pylori* therapy from trial and error to antimicrobial stewardship. *Antibiotics (Basel)*. 2020; 9(10): 671. doi: 10.3390/antibiotics9100671
62. Kaptechuk TJ, Shaw J, Kerr CE, Conboy LA, Kelley JM, Csordas TJ, Lembo AJ, Jacobson EE. Maybe I made up the whole thing: placebos and patients' experiences in a randomized controlled trial. *Culture, Medicine, and Psychiatry*. 2009; 33(3): 382-411. doi: 10.1007/s11013-009-9141-7

Conflict of interest: The author declares the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical issues: The author completely observed ethical issues including plagiarism, informed consent, data fabrication or falsification, and double publication or submission.

Author declarations: The author confirms that they have followed all relevant ethical guidelines and obtained any necessary IRB and/or ethics committee approvals.